CENTOGENE N.V. (CNTG): Price and Financial Metrics
CNTG Price/Volume Stats
| Current price | $1.20 | 52-week high | $2.52 |
| Prev. close | $1.26 | 52-week low | $0.61 |
| Day low | $1.20 | Volume | 505 |
| Day high | $1.21 | Avg. volume | 566,624 |
| 50-day MA | $1.15 | Dividend yield | N/A |
| 200-day MA | $1.02 | Market Cap | 32.50M |
CNTG Stock Price Chart Interactive Chart >
CNTG Stock Summary
- CENTOGENE NV's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 93.38% of US listed stocks.
- As for revenue growth, note that CNTG's revenue has grown -78.63% over the past 12 months; that beats the revenue growth of just 2.27% of US companies in our set.
- CENTOGENE NV's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -165.74%, greater than the shareholder yield of only 3.14% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to CENTOGENE NV are GTH, DOOO, FALC, DESP, and CLRO.
- CNTG's SEC filings can be seen here. And to visit CENTOGENE NV's official web site, go to www.centogene.com.
CNTG Price Target
For more insight on analysts targets of CNTG, see our CNTG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $19.32 | Average Broker Recommendation | 1 (Strong Buy) |
CENTOGENE N.V. (CNTG) Company Bio
Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.
Latest CNTG News From Around the Web
Below are the latest news stories about CENTOGENE NV that investors may wish to consider to help them evaluate CNTG as an investment opportunity.
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture TransactionLifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing services to patients, health systems, biopharma clients, and research institutions across the Gulf Cooperation Council (GCC) region CENTOGENE to receive an additional $10 million upfront JV milestone payment, following an initial $30 million investment from Lifera. Company eligible for additional performance-related milestone payments and revenue-based royalt |
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and ParkinsonismResults From Landmark Study Published in Brain JournalCollaborative research initiative leveraged CENTOGENE’s Whole Exome Sequencing (WES) to reveal disease-causing gene called ACBD6 (Acyl-CoA Binding Domain Containing 6) Over seven years, a total of 45 affected individuals from 29 independent families in Southeast Asia, Central Asia, the Middle East, Europe, and North and South America have been identified Study guides further research for potential treatments, including genetic causes and path |
CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic OfferingIncorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biologyCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the expansion of MOx, the Company’s multiomic diagnostic portfolio, now incorporating cutting-edge transcriptomic analysis. CENTOGENE’s MOx 2.0 is a single |
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment ConferenceCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that CENTOGENE CEO Kim Stratton will present in the virtual track at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, and invites investors to participate via virtual one-on-one meetings with Ms. Stratton and CENTOGENE CFO |
CENTOGENE Reports First Half 2023 Financial ResultsStrong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial PerformanceFirst half 2023 total revenues with double-digit growth of 15.1% at €24.6 millionBoth Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue growth between 10% to 15%Recently announced strategic collaboration with Lifera, a biopharmaceutical company wholly-owned by the Saudi Arabia Public Investment Fund (PIF), strengthens glo |
CNTG Price Returns
| 1-mo | -4.50% |
| 3-mo | 13.21% |
| 6-mo | 64.99% |
| 1-year | 64.36% |
| 3-year | -89.75% |
| 5-year | N/A |
| YTD | 29.03% |
| 2022 | -82.21% |
| 2021 | -51.50% |
| 2020 | 7.05% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...